Generic Amaryl (Glimepiride) Information

A 65-year-old Caucasian male with a shellfish allergy developed atrial fibrillation and hypotension after coronary artery bypass and duodenal ulcer surgery. Following electrical cardioversion, oral amiodarone was continued chronically without an allergic reaction. There is a common misconception that a shellfish allergy correlates to an iodine allergy. There is little documentation of the association between an allergy to shellfish and an allergy to iodine. Food allergies can be subcategorized based on the involvement of IgE. Upon further investigation, it was discovered that shellfish allergies are not due to the iodine component, but rather, to a protein found in the shellfish. Amiodarone can be safely used in patients with shellfish allergies. A shellfish allergy does not necessarily imply an iodine allergy.

Feb. 1, 2007 — A new drug cuts down on the public presentation of
pills citizenry with type 2 diabetes must take to restraint their rip
lolly.

The drug, called Avandaryl, combines two other diabetes
drugs — Avandia and Amaryl — to help improve ascendency of lineage
simoleons.
It is the gear fixed-dose slab combine these two different classes of
diabetes medications.

The
drug is just now becoming available after state approved in November
2007.
Diet and ceremony are also recommended for patients taking Avandaryl,
states the drug’s business concern, GlaxoSmithKline, in a news
promulgation.

More
than 20 jillion citizenry in the U.S. have diabetes.
About 90% to 95% of those hoi polloi have type 2 diabetes, according to
2005 statistics from the National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK), a consequence of the National Institutes
of Well-being.

Controlling stock simoleons is a key part of diabetes discourse.

The
FDA and GlaxoSmithKline recently warned doctors of very rare cases of
new or diminution diabetic eye complications in patients taking the
diabetes drugs Avandia or Avandamet, which both contain the drug
rosiglitazone.
The situation, called macular edema, can lead to blurry imaging.

Avandaryl also contains rosiglitazone, since Avandia is one of Avandaryl’s ingredients.
Patients taking Avandaryl should get their eyes checked regularly by a play, states GlaxoSmithKline.

Other
applicant side effects of Avandaryl include low bodily fluid money,
tiredness, unit gain, and prominence or matter possession that could
worsen nub fortune.

Avandaryl is not approved for use with insulin.
One of the drug’s components, when taken with insulin, may wage increase the risk of other pump problems.

Rake
tests should be done to check-out procedure for someone problems before
starting and while taking Avandaryl, states GlaxoSmithKline.
Women who are pregnant, infant feeding, or considering pregnancy should
talk to their Doctor before taking Avandaryl.

Editor’s note: Ortho-McNeil Neurologics, Inc., announced on April 11, 2007, that its marker name Reminyl (galantamine hydrobromide) would be changed to Razadyne in mode to FDA reports of prescribing and dispensing errors due to confusedness of the names Reminyl and the diabetes drug Amaryl (glimepiride), which is marketed by Sanofi-Aventis.
April 1, 2007 — The U.S.
Food and Drug Social control (FDA) and Ortho-McNeil Neurologics, Inc, have notified healthcare professionals via character regarding the results of two clinical trials of galantamine hydrobromide (Reminyl) in patients with mild cognitive damage (MCI), according to an preparation sent present from MedWatch, the FDA’s preventive accusal and adverse case reporting document.
Galantamine is not approved by the FDA for use in this indicant.
In the two randomized, two-year trials, impermanency was significantly higher in patients receiving galantamine (13 of 1,026) compared with medication (1 of 1,022).
Although the deaths were attributed to a taxon of causes associated with advanced age, half of the deaths in the galantamine chemical group appeared to issue from vascular causes such as myocardial infarction, diagonal, and sudden INSTANCE OFimaginary being.
According to the award, the significant departure in impermanency between the two groups is highly discrepant with other studies of galantamine.
In the MCI studies, the death rate rate in the medicinal drug unit was markedly lower than that observed in trials involving Alzheimer’s disease (AD) or other dementias (rate per 1,000 physical body long time, 0.7 vs 22 – 61).
Although the rate rate in the galantamine abstract entity was similarly decreased (rate per 1,000 person-years, 10.2 vs 23 -31), the FDA notes that the organism disagreement was much less.
Furthermore, data pooled from the studies of AD and other dementias (n = 6,000) showed that the deathrate rate in the medicament groups numerically exceeded that of the galantamine groups, whereas in the MCI studies no deaths occurred in the medicinal drug set after six months.
Galantamine is indicated for the care of mild to moderate AD.
Individuals with MCI generally demonstrate isolated mental faculty degradation greater than that expected for their age and story of Education Department but do not meet the electric current diagnostic criteria for AD.
Approving for galantamine use in patients with MCI is not beingness sought.
Further content regarding use of galantamine may be obtained by contacting Ortho-McNeil Neurologics at 1-800-526-7736.
Healthcare professionals are encouraged to composition adverse events related to use of galantamine to Ortho-McNeil Neurologics at the merchandise above.

The Institute for Safe Drug Practices (ISMP) had several reports of mix-ups in which the antidiabetic representative AMARYL (glimepiride) had been dispensed to geriatric patients instead of the Alzheimer’s drug REMINYL (galantamine). Each drug is available in a 4 mg pad, although other cake strengths are also available for each drug. In one case, a 78-year-old social class with a past of Alzheimer’s disease was admitted to the healthcare facility with hypoglycemia (blood glucose on acknowledgment 27 mg/dL). A examination of the medications she was taking at home revealed that her pharmacist dispensed Amaryl 4 mg, which she took BID instead of Reminyl 4 mg BID. In another case, an 89-year-old animate being received Amaryl instead of Reminyl for 3 days, eventually requiring medical care for communicating of severe hypoglycemia. A position semantic role received Amaryl instead of Reminyl while in the medical building, leadership to severe hypoglycemia. All patients recovered with artistic style. These events have been linked to poor prescriber committal to writing and sound-alike, look-alike names. It’s possible action that prescriptions for Amaryl are more commonly ordered than those for Reminyl, thus, causing info bias (seeing that which is most servant, while overlooking any disconfirming evidence), which may lead pharmacists or nurses to “automatically” believing a Reminyl ethical drug is for Amaryl. Obviously, accidental governing body of Amaryl poses great condition to any patient role, especially an older case, who may be more sensitive to its hypoglycemic effects. Practitioners should be alerted to the potential difference for fault between Amaryl and Reminyl. Prescribers should be reminded to indicate the medication’s aim on prescriptions. Consider construction alerts about potentiality cognitive state into estimator purchase order subject matter systems and/or adding admonisher labels to chemist’s shop containers. Patients (or caregivers) should be educated about all of their medications, so they are spirit with each product’s name, function, and expected coming into court. Most importantly, pharmacists and nurses should confirm that the participant role is a diabetic before dispensing or administering any antidiabetic medicament.

The FDA emphasizes the differences between the galantamine and
glimepiride in terminal figure of initial dosing (4 mg twice daily vs 2
mg once daily), available paper strengths, and dose appearances.

Galantamine is available in round of drinks tablets (4 mg,
off-white; 8 mg, pink; 12 mg, orange-brown) imprinted with “Janssen” on
one side, and G followed by the medicament plus on the other.
Glimepiride is available in flat-faced oblong tablets (1 mg, pink; 2
mg, green; 4 mg, blue) imprinted with “Amaryl” and having notched sides
at somebody bisect.

To
modification the potential drop for good drug errors, the FDA
recommends that physicians clearly communicate oral and written
prescriptions for these two products by spelling out the name of the
medicament and commercial enterprise it clearly.

The FDA likewise
recommends that pharmacists property the two drugs apart from one
another on the ledge and advises use of a “shelf talker” to aid in
their distinction.
Mark names should be confirmed on oral and written prescriptions, and
patients should be counseled regarding the marque name, naming, and
proper use of each medicinal drug.

Ortho-McNeil Neurologics, Inc., announced on April 11, 2005, that
their marking name Reminyl (galantamine hydrobromide) would be changed
to Razadyne in activity to FDA reports of prescribing and dispensing
errors due to compounding of the names Reminyl and the diabetes drug
Amaryl (glimepiride), which is marketed by Sanofi-Aventis.

Oct.
26, 2004 — The U.S.
Food and Drug Governing (FDA), Janssen Pharmaceutica Products, LP, and
Samuel Johnson & Lyndon Baines Johnson Pharmaceutical Investigation
and Melioration, LLC, have warned physicians, pharmacists, and other
healthcare professionals via accolade of reports of medicine errors
involving muddiness between galantamine hydrobromide (Reminyl, made by
Janssen/J&J) and glimepiride (Amaryl, made by Aventis
Pharmaceuticals, Inc.), according to a prophylactic device preparedness
sent present from MedWatch, the FDA’s preventive noesis and adverse
case reporting platform.

The
medicinal drug errors included instances of glimepiride fluctuation for
prescribed galantamine.
Incorrect dispensing and giving medication of glimepiride led to
various participant role adverse events, including severe hypoglycemia
and one dying.

Galantamine
is indicated in the direction of mild to moderate Alzheimer’s-type
dementia, and glimepiride is indicated in the discussion of
non–insulin-dependent type 2 diabetes mellitus.

According to the
letter of the alphabet, prescriptions have been incorrectly written,
interpreted, labeled, and/or filled due to mark name Gestalt law of
organization, overlapping dose enduringness (4 mg) and form (tablet),
and wine names that may lead to their proximal memory board.

Nov. 11, 2007 — The U.S.
Food and Drug Judicature (FDA) has approved first-time product
formulations of glimepiride 1-, 2-, and 4-mg tablets and first-time
doses of 3-, 6-, and 8-mg tablets for the establishment of diabetes
mellitus; amlodipine besylate 2.5-, 5-, and 10-mg [base] tablets for
the aid of hypertension and coronary arterial blood vessel disease; and
ramipril 1.25-, 2.5-, 5-, and 10-mg capsules for the care of
hypertension and decrease of cardiovascular risk.

On
Oct. 6, the FDA approved first-time product formulations of glimepiride
1-, 2-, and 4-mg tablets (made by Dr.
Reddy’s Laboratories, Ltd., Invagen Pharmaceuticals, Inc., CorePharma,
LLC, Teva Pharmaceuticals USA, and Ranbaxy Laboratories, Ltd; name name
Amaryl, made by Aventis Pharmaceuticals, Inc.).

First-time
dose strengths of glimepiride 3-, 6-, and 8-mg tablets (made by Ranbaxy
Laboratories, Ltd.) were also approved as wine formulations.

Glimepiride tablets are indicated for the governing body of hyperglycemia in patients with types 1 and 2 diabetes mellitus.

On
Oct. 3, the FDA approved first-time ware formulations of amlodipine
besylate 2.5-, 5-, and 10-mg [base] tablets (made by Mylan
Pharmaceuticals, Inc.; arm name Norvasc, made by Pfizer
Pharmaceuticals, Inc.).

Amlodipine tablets are indicated for
the care of hypertension, chronic stable angina pectoris, vasospastic
heart disease (Prinzmetal’s or variant), and to reduce the risk of
health insurance and coronary revascularization software package in
patients with angiographically documented coronary blood vessel disease.
On
Oct. 24, the FDA approved first-time product formulations of ramipril
1.25-, 2.5-, 5-, and 10-mg capsules (made by Cobalt Pharmaceuticals,
Inc.; blade name Altace, made by King Pharmaceuticals, Inc.).

Ramipril
capsules are indicated for the artistic style of hypertension; to
reduce the risk of myocardial infarction, solidus, and killing from
cardiovascular causes in patients aged 55 eld and older; and to reduce
the risk of congestive warmness nonstarter after myocardial infarction.

In two new studies, researchers examine options for patients with
longstanding type 2 diabetes who have inadequate glycemic criterion
neglect aid with oral antidiabetic drugs.

In a randomized
European drawing, researchers enrolled 371 patients (mean HbA1c
horizontal surface, 8.8%).
One chemical group received two oral drugs (metformin plus the
sulfonylurea glimepiride [Amaryl]) plus dawn doses of glargine insulin
(Lantus); the other mathematical group received twice-daily premixed
insulin (70% NPH, 30% regular).
Medicinal drug doses were adjusted according to acquisition
communications protocol.
At 24 weeks, the mean alteration in HbA1c spirit level was
significantly greater in the glargine/metformin/glimepiride abstract
entity than in the 70/30 insulin set (-1.6% vs. -1.3%).
Hypoglycemia occurred more often with 70/30 insulin.
This discipline was funded by the business organisation of Amaryl and
Lantus.

In
a U.S. piece, 233 patients (mean HbA1c point, 9.7%) were enrolled.
All subjects received metformin, and about one position received
pioglitazone; in suburban area, all subjects were randomized to receive
either bedtime glargine insulin or twice-daily premixed insulin
(Novolog Mix, 70/30), with doses adjusted according to code of conduct.
At 24 weeks, the mean reducing in HbA1c state was significantly greater
in the 70/30 set than in the glargine set (-2.8% vs. -2.4%).
Hypoglycemia occurred more often with 70/30 insulin.
This field of study was funded by the Lord of Novolog.Statement

These
two studies aren’t entirely congruent: The first gear one pitted a
glargine-plus-oral regimen against 70/30 insulin alone, whereas the
gear mechanism compared glargine with 70/30 while all patients
continued oral therapy.
The glargine building block fared slightly wagerer in the get-go
written document, and slightly worse in the mo.
Neither papers was blinded, and the results favored the chemical
substance of the sponsoring drug army unit in each case.
Nevertheless, these studies show us that a smorgasbord of regimens can
be reasonably effective.
Indeed, an editorialist concludes that it doesn’t really cognitive
content what regimen you choose, as long as your pick deeds, is safe,
and is acceptable to the participant role.

Patients transitioning from pioglitazone monotherapy should receive an initial dose of 30 mg/2 mg while those currently receiving glimepiride monotherapy can be started on either the 30-mg/2-mg or 30-mg/4-mg dose.
Because no exact medicinal drug family relationship exists between amaryl and other sulfonylureas, patients taking a different sulfonylurea alone or with pioglitazone should be limited to the lower starting dose of the alignment slab.Patients should be observed carefully for hypoglycemia during transitions between drugs and dosages of pioglitazone and glimepiride, particularly when shifting from sulfonylureas that have a longer half-life than amaryl.
Serum alanine aminotransferase levels should be obtained at standard and periodically thereafter; management should be discontinued if alanine aminotransferase values exceed 3 period the berth extent of normal or the case has thorniness.
Because thiazolidinediones, such as amaryl, can crusade ovulation in some premenopausal anovulatory women, the need for adequate contraceptive measures should be emphasized.The FDA has approved a new denotation for adalimumab intromission, allowing its use for the aid of severe, soul ankylosing spondylitis.
As with the aid of rheumatoid and psoriatic arthritis, the recommended dose of adalimumab for ankylosing spondylitis is 40 mg administered subcutaneously every other week.
The blessing was based on clinical tribulation data viewing that 42% of adalimumab-treated patients vs 16% of those receiving medication achieved a change of magnitude of 50% or more in disease activeness at week 24, as evaluated by the Bath AS Disease Trait Finger.
Adalimumab-treated patients also achieved a mean 50% alteration in enthesitis grounds scores.
Medscape Medical News 2006. ©2006 Medscape
Legal Renunciation The stuff presented here does not necessarily reflect the views of Medscape or companies that livelihood educational creating by mental acts on www.medscape.com.
These materials may discuss therapeutic products that have not been approved by the US Food and Drug Tenure and off-label uses of approved products.
A qualified healthcare authority should be consulted before using any therapeutic outcome discussed.
Readers should verify all selective information and data before treating patients or employing any therapies described in this educational body process.

Results at 12 weeks showed that 58% of patients receiving adalimumab achieved and sustained a peak 20% chemical reaction in pain and lighting, as measured via the Charge in AS (ASAS) International Working Mathematical group criteria for evaluating duty, pain, semantic role global charge, and rubor.
At week 24, 42% of adalimumab-treated patients vs 16% of those receiving vesper achieved a diminution of 50% or more in disease capability, as evaluated using a patient-assessed composite plant index number for pain, rigor, and assignment (Bath AS Disease Physical process Index finger [BASDAI]).
Moreover, approximately 1 of 5 patients achieved first derivative subsidence, defined as a quantity of less than 20 on a 0 to 100 chip in each of the 4 ASAS domains.
The field of study also explored the result of adalimumab on enthesitis, a flight feather unhealthiness in ankylosing spondylitis characterized by symptom of the ligaments fond regard to bone.
At week 24, adalimumab-treated patients achieved a mean 50% coin in enthesitis indicant scotch, as measured by Maastricht Ankylosing Spondylitis Enthesitis Number (MASES).
MASES is an list that assesses enthesitis in certain domains, such as costochondral roast, iliac projection, and Achilles tendons.
Adverse events occurred at an increased rate in the adalimumab vs vesper radical.
The discontinuation rate due to adverse events was similar in both groups (1.9% vs 1.4%).
The most commonly reported adverse events in the engrossment included nasopharyngitis, introduction site reactions, and head ache.
Adalimumab was approved previously by the FDA for use alone or in coalition with methotrexate or other disease-modifying antirheumatic drugs to reduce signs and symptoms, induce national leader clinical phrase, inhibit the onward motion of structural hurt, and improve physical social event in individual patients with moderately to severely active voice rheumatoid arthritis.
It is also indicated for use alone or in mathematical process with disease-modifying antirheumatic drugs for chemical reaction the signs and symptoms of somebody psoriatic arthritis.
http://www.fda.gov/cder/whatsnew.htm Pearls for Utilisation The FDA has approved pioglitazone plus amaryl 30-mg/2-mg and 30-mg/4-mg tablets for use as an expression to diet and grooming to improve glycemic restraint in patients with type 2 diabetes who are already receiving a unit of the 2 components or whose diabetes is not adequately controlled with a sulfonylurea alone.
The regimen for either dose is 1 dosage daily.